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Sophisticated protein kinase networks, empowering complexity in higher organisms,
are also drivers of devastating diseases such as cancer. Accordingly, these enzymes
have become major drug targets of the twenty-first century. However, the holy grail of
designing specific kinase inhibitors aimed at specific cancers has not been found. Can
new approaches in cancer drug design help win the battle with this multi-faced and
quickly evolving enemy? In this perspective we discuss new strategies and ideas that
were born out of a recent breakthrough in understanding the molecular basis underlying
the clinical success of the cancer drug Gleevec. An “old” method, stopped-flow kinetics,
combined with old enzymes, the ancestors dating back up to about billion years, provides
an unexpected outlook for future intelligent design of drugs.
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The Beauty and Curse of Protein Kinases
Why are we more sophisticated than a yeast cell? One of the reasons is protein kinases, that
exploded both in numbers (more than 500 in humans compared to 130 in yeast) and sophistication
with the development of multicellularity (Richter and King, 2013). The evolution of specialized
kinases enabled complex regulatory networks in higher organisms thereby providing a huge
evolutionary edge. However, a crack in this machinery as little as a single point mutation in a kinase
can cause cancer—an Achilles heel that has elevated protein kinases into the number one drug
target of the twenty-first century (Cohen, 2002; Cohen and Alessi, 2013; Wang et al., 2014). The
stringent requirements for catalyzing a chemical reaction that uncatalyzed would take about 7000
years (Stockbridge andWolfenden, 2009; Kerns et al., 2015) resulted in a strong conservation of the
active sites, which have thus been extensively targeted in cancer drug development. Unfortunately,
inhibitors targeting the ATP binding site tend to be unselective due to this active site conservation,
leading to unwanted side effects. The popularity of the field of protein kinase inhibition as well
as alternative strategies such as inhibition of substrate binding and protein interaction sites is best
reflected by a number of recent reviews (Wang et al., 2014 and a special issue in ACS Chemical
Biology, 2015). In addition, new high-throughput assays are being constantly developed to facilitate
screening of the compounds (Acker and Auld, 2014), however, themajor goal of the pharmaceutical
industry to develop specific kinase inhibitors remains a daunting challenge.
The Wonder Drug of the Century
Gleevec is an exception, as it has great specificity for the onco-protein BCR-Abl (Capdeville et al.,
2002; Cohen et al., 2002). The BCR-Abl fusion protein results from reciprocal translocation between
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chromosome 9 and chromosome 22, widely known as the
Philadelphia translocation, leading to a constitutively active
kinase (Rowley, 1973; Daley and Baltimore, 1988). Gleevec was
approved by the FDA for clinical use in 2001, and has proven to
be remarkably successful in treating chronic myeloid leukemia
(CML) and gastrointestinal stromal tumors. Its success generated
tremendous enthusiasm in the scientific community and even
general public, after the reports about “new ammunition in the
war against cancer” and its outstanding effectiveness were picked
up by the media (Lemonick and Park, 2001; Newsweek, 2001;
Wade, 2001). Gleevec was viewed as a “proof of principle drug,”
which showed the possibility of rational design of an inhibitor
that would specifically target a kinase of interest. Unfortunately,
tireless efforts aimed at understanding themolecularmechanisms
of Gleevec’s selectivity over the last 20+ years were mostly
unsuccessful, and the original expectations of a steady stream
of new therapeutics emerging from basic research turned out to
be overoptimistic. As reviewed recently (Cohen and Alessi, 2013;
Wang et al., 2014) since Gleevec’s triumph, approximately 20 new
kinase inhibitors were developed and entered clinical use. This
is a rather small number considering that there are more than
500 human kinases and multiple inhibitors are needed for each
of them to combat the inevitable mutations that lead to drug
resistance. A fundamental pitfall in drug development is a lack of
understanding of the detailed biophysical mechanisms that make
inhibitors successful.
Conformational Selection and the Famous
“DFG-Loop”
In the search for the physical determinants of Gleevec selectivity,
the DFG – loop (Asp-Phe-Gly), a 100% conserved element in the
kinome (Figure 1A), stood out as a structural feature that differs
between kinases that bind Gleevec tightly or weakly. In the x-
ray structure of Abl, this loop adopts an “out” conformation in
both the apo and Gleevec-bound protein, while in the closest
homolog and weak binder Src kinase it occupies a binding-
incompetent “in” conformation in the apo protein that would
have to move into the “out” position to accommodate the drug
(Xu et al., 1997; Schindler et al., 2000; Nagar et al., 2003; Seeliger
et al., 2007). These structures, together with the fact that the
active conformations look too similar to provide selectivity,
shifted attention toward structural determinants of inactive
conformations.
It was hypothesized that the preferential occupancy of the
DFG-out state by Abl but not Src is the primary source of Gleevec
selectivity. This model of an equilibrium between binding-
incompetent (DFG-in) and competent state (DFG-out) (KCS)
being the source for differential drug affinities is a classical
conformational selection mechanism (Cowan-Jacob et al., 2005;
Dar et al., 2008; Shan et al., 2009; Aleksandrov and Simonson,
2010; Lovera et al., 2012; Lin and Roux, 2013; Lin et al., 2014) that
has recently gained popularity in biology (see the special issue
of Biophysical Chemistry and references within) (Biophysical
Chemistry, 2014) (Scheme in Figure 1E). This hypothesis was
further substantiated by the observation that less selective
inhibitors such as Dasatinib do not differentiate between “in” and
“out” conformations of the DFG-loop.
The elegance of this hypothesis, the direct observation of two
different states of the DFG-loop in crystal structures and the
excellent fit to the “expected model” of drug selectivity resulted in
a wealth of literature focusing on this aspect of protein dynamics.
A variety of approaches, both experimental (Vogtherr et al., 2006;
Vajpai et al., 2008) and computational, were taken to quantify the
free energy profile of the DFG-loop dynamics (Levinson et al.,
2006; Aleksandrov and Simonson, 2010; Lovera et al., 2012; Lin
and Roux, 2013; Lin et al., 2014; Meng et al., 2015). However,
experimental studies of DFG-loop equilibrium in solution
were complicated by high dynamics of this loop hampering
quantification of this equilibrium. Some computational reports
seemed to quite impressively quantitatively recapitulate the
experimentally observed Gleevec affinities for the different
kinases (Lin and Roux, 2013; Lin et al., 2014) despite the widely
acknowledged current computational limitations for accurate
energy calculations (Shaw et al., 2010; Piana et al., 2011;
Lindorff-Larsen et al., 2012). Other computational studies were
contradictory, and results varied depending on the methodology
used. Despite the lack of direct experimental observation of
the DFG-loop equilibrium, the DFG-loop hypothesis underlying
selectivity became so popular that all active site kinase inhibitors
were classified as class I (binding to both DFG-in and -out
conformations) and class II (binding exclusively to the DFG-out
state).
Although large screens hinted at a trend that class-II inhibitors
may be more selective, many counterexamples of selective type I
and promiscuous type II inhibitors were observed (Davis et al.,
2011; Treiber and Shah, 2013). These data suggested that the
DFG-loop may not be as essential for selectivity as initially
thought. Paradoxically, despite its logical appeal, the DFG-loop
conformational selection model did not lead to new highly
selective kinase drugs. What is missing?
Old Fashioned?
A surprising breakthrough came from an unexpected direction.
A new method of molecular time-travel back to the origin of
these kinases and resurrection of their evolutionary trajectories
into the modern kinases delivered the mechanism of Gleevec
selectivity. Ironically, not only the resurrected enzymes that
provided the understanding were old, so was the technique that
yielded the answer. Stopped-flow kinetics, first described in the
1940s (Chance, 1940; Gibson et al., 1955) and often perceived
as old-fashioned, has enormous potential when it comes to
characterizing enzyme–drug interactions.
However the first hint for a new and unanticipated model
came from following Gleevec binding to human Abl and Src
by NMR, which revealed a slow conformational transition after
drug binding that was different for the two kinases. Moreover,
binding was sensed by residues far from the binding pocket
indicating propagated conformational changes (Agafonov et al.,
2014). Stopped-flow fluorescence experiments with modern Abl
and Src (Agafonov et al., 2014) delivered quantification of the
steps observed in the NMR experiments.
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FIGURE 1 | Novel model of Gleevec binding to tyrosine kinases with
quantification of individual steps. (A) Top: Crystal structure (4CSV)
(Wilson et al., 2015) of last common ancestor of Src and Abl (ANC-AS)
bound to Gleevec (magenta); the DFG loop is shown in stick. Bottom:
DFG-loop in the -in (2SRC) and -out (4CSV) conformation is shown with
Gleevec bound (magenta surface). Only the DFG-out conformation is
compatible with Gleevec binding. (B–D) Binding and dissociation kinetics of
Gleevec to Abl and Src measured by stopped-flow fluorescence (for details
see Agafonov et al., 2014). (B) Gleevec binding to Abl at 5◦C is biphasic with
the fast phase corresponding to the physical binding step and slow phase
corresponding to the induced fit step. Blue – experimental data, black –
double-exponential fit. (C) Dependence of kobsconf [observed rate of the
induced fit step, see scheme in (E)] on Gleevec concentration. (D)
Dissociation kinetics of Gleevec from Abl and Src measured by dilution of
enzyme-Gleevec complexes, which determines the kconf- rate constant [see
scheme in (E)]. (E) Gleevec binding scheme showing three distinct steps:
conformational selection step, physical binding of the drug to the binding
competent state, and the following conformational transition (induced fit).
Equilibrium constants corresponding to each step (Kcs, Kbind, and KIF)
determine the overall binding affinity (KD): KD =
(KCS + 1) • Kbind • KIF
(1+ KIF )
.
Contrary to the previously explored models, the dominant
role in Gleevec’s selectivity belongs to the conformational
transitions in the kinase-drug complex (induced fit, Figure 1E),
and not to the DFG-loop conformational selection or the physical
binding step. These induced fit transitions are the slowest steps
with the forward rate (kconf+) roughly 10 times faster in Abl
compared to Src (Figure 1C). The rate of the reverse step,
kconf−, measured by dilution experiments, is 70-fold slower in
Abl (Figure 1D), leading to a 700-fold difference in the overall
equilibrium (KIF) (Figure 1E). Because of simple principles of
coupled equilibria, this 700-fold shift of the induced fit step
equilibrium results in a 700-fold increase in the overall affinity
for Gleevec, therefore accounting for most of the observed 3000-
fold difference [the remaining four-fold difference comes from
the DFG-loop conformational selection (see below)]. The actual
binding step to the two kinases is nearly identical highlighting
the limited usefulness of docking studies that play a prominent
role in the current computational efforts in drug design. This
“numbers-game” from the stopped-flow experiments delivered a
new mechanism that quantitatively accounts for the long-known
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difference in kinase affinities for Gleevec and hence answers the
long-standing question of specificity (Agafonov et al., 2014).
Inspired by the new findings for Gleevec we advocate
that the full energy profiles need to be considered, since the
differences between kinases are rooted in the differences of
the free energies of all states along the binding trajectory. The
role of induced fit in substrate binding to enzymes for better
substrate positioning for catalysis has been appreciated, however
its experimental quantification is still not a commonly applied
practice. Possible roles of induced fit for drug binding was
also nicely discussed (Copeland, 2011), but its role in inhibitor
affinity and selectivity remains undervalued. Notably, only the
local rearrangements around the drug-binding pocket instead
of long-range conformational transitions are often considered
in rational drug design. Such long-range dynamics is, in fact,
in play for the Gleevec specificity, as exposed by the ancestor
resurrection.
The Devil is in the [Atomistic] Details
While a physical chemist might be satisfied having figured out the
kinetic scheme with hard numbers that rationalize the different
drug affinities, the structural biologist will ask: which residues
are responsible for the different energy landscapes? This might
appear easy—just start mutating residues in the weak binding
Src to mimic Abl. However, in spite of a large number of
tested substitutions, such efforts were not successful indicating
that the underling mechanism for Gleevec selectivity is more
complex than anticipated (Seeliger et al., 2007). This approach
although tempting has the following unavoidable drawbacks.
Many differences accumulated during divergent evolution result
from neutral drift (substitutions that are neutral for function and
thus are not under selective pressure), and basically represent
noise, from which one needs to fish out the sequence changes
linked to the property of interest. To make the mater worse,
some amino acid changes only come into play in the background
of other mutations – a phenomenon called epistasis (Depristo
et al., 2005; Harms and Thornton, 2013; Boucher et al.,
2014). As a consequence, simple sequence swaps between two
modern enzymes don’t work because they miss the effect of the
corresponding evolution of the amino acid background.
As illustrated in Wilson et al. (2015), ancestral sequence
reconstruction (ASR) can be a powerful tool to overcome this
challenge. ASR is a rapidly developing method that allows
the inference of now nonexistent ancestral sequences using
the growing amount of sequence information available. This
approach was already formulated more than 50 years ago by
Pauling and Zuckerkandl (1963). Modern enzymes (even the
ones close in structure) still often differ from each other by 100+
residues. Such divergence in combination with neutral drift and
epistasis makes it virtually impossible to rationally analyze the
sequence differences. Ancestral reconstruction kills two birds
with one stone. First, the sequence differences between two
ancestors (or an ancestor and a modern protein) are smaller
than those between the two modern enzymes, which makes a
productive analysis of sequences more probable. Second, swaps
between ancestor and its “grand-grand-children” can indeed
shed light into atomistic mechanisms since epistasis is naturally
accounted for.
In the work of Wilson et al. (2015) a phylogenetic tree of
76 modern kinases from different families and organisms of
non-receptor tyrosine kinases was reconstructed, and protein
sequences corresponding to key evolutionary branching points
were resurrected (Figure 2A). Remarkably, all reconstructed
ancient enzymes, differing by up to 100 amino acids from
anything you can find today in nature, are fully active! The
common ancestor of Src and Abl (called ANC-AS) had an
intermediate affinity for Gleevec that increased along the
evolutionary branch leading to Abl and decreased along the Src
branch (Figure 2B).
Combining ancestral reconstruction with their Gleevec
binding kinetics and structure illustrates the evolution of
divergent energy landscapes (Figure 2C). Of interest to
drug designers, it indeed delivered the atomistic mechanism
responsible for Gleevec selectivity. Fifteen amino acid differences
(out of 146) were identified to encode Gleevec specificity
for Abl (Figure 2D) (Wilson et al., 2015). Their role in the
induced fit step can now be rationalized structurally including
stabilizing effects on drug–protein interaction and tuning
differential flexibility via H-bonds remote from the drug-binding
site (Figure 2D) (Wilson et al., 2015). So indeed long-range
dynamics and epistasis are in play for Gleevec binding as first
seen in the NMR studies (Agafonov et al., 2014) and hinted by
the unsuccessful early swop approach (Seeliger et al., 2007).
Interestingly, the same residues correlated well with several
resistant mutations found in patients who developed Gleevec
resistance (Wilson et al., 2015). In other words, current evolution
appears in these “dynamic hotspots,” and the rationalization
of the underlying atomistic mechanism for Gleevec resistance
might help in designing drugs that overcome this detrimental
evolution of cancer cells.
New Tool in Biophysics—Ancestral
Sequence Reconstruction (ASR)
The reader should wonder why an evolutionary approach is
useful to solve a mechanism of a modern-day, man-made
molecule? Obviously Abl did not evolve to bind Gleevec and be
“strangled” by it! Rather, Gleevec accidently took advantage of
differences in kinase regulation created by divergent evolution.
While kinases are similar in their turnover rates upon activation,
they vary drastically in their regulatory mechanisms. Such
evolution of regulation became necessary with the developing
of multicellularity and increasingly complex signaling cascades.
Although in the case of Gleevec phylogenetic considerations were
not part of the design, and overlap between Gleevec’s selectivity
and evolution of regulation was coincidental, we propose that
targeting the unique energy landscapes underlying the regulatory
features of a kinase of interest can be a powerful strategy for
developing new selective inhibitors.
Evolution is rooted in the most fundamental process of
random mutations, and driven by selection for better fitness.
In light of this, the weird link between Gleevec selectivity and
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FIGURE 2 | Ancestral sequence reconstruction reveals the evolution
of the energy landscape for Gleevec binding and identifies the
residues responsible for Gleevec selectivity. (A) Phylogenetic tree of Abl
and Src families showing the reconstructed nodes. Timeline indicates
approximate age of the reconstructed ancestors. The corresponding
sequences including the alignment are given in Wilson et al. (2015) (B)
Inhibition constants Ki for each kinase were determined from the activity
versus drug concentration profiles showing a gradual change in Gleevec
affinity from the weak binder Src to the tight binder Abl via the intermediate
binder ANC-AS. Same colors are used as defined in (A). (C) Schematic
representation of the evolution of the Gleevec binding energy landscape
based on data from Wilson et al. (2015). The major difference between
kinases is in the induced fit step. Conformational selection step provides a
minor contribution and physical binding step is nearly identical in all kinases.
(D) Substitution of only 15 residues in the N-terminal lobe of ANC-AS
(resulting in ANC-AS(+15)) guided by ancestral sequence reconstruction,
structure, and biochemical analysis (Wilson et al., 2015) results in dramatic
increase in Gleevec affinity (right panel). Ten of the amino acid changes from
ANC-AS into the corresponding residues in Abl are indicated by arrows. A
subset of these identified mutations disrupt hydrogen bonds (shown as
dotted lines) that are present in weak binders (some highlighted by red
circles) leading to an increase in kinase flexibility for the strong binders
thereby enabling an efficient induced fit step. Some panels in Figures 1, 2
are adapted from Agafonov et al. (2014) and Wilson et al. (2015).
evolution is actually not so far-fetched. Evolution as a result
of chance shows itself in this story as a friend and foe: it led
to the development of humans, but also to cancer and drug
resistance. Using ASR to solve amodern cancer drugsmechanism
is unorthodox, since until recently this method has been applied
to recapitulate nature’s paths to modern proteins with differential
functions. Arguably the most famous ASR story has come from
the Thornton lab in their successful inference of ancient corticoid
receptors (Thornton et al., 2003; Ortlund et al., 2007; Bridgham
et al., 2009). A story spanning over a half a dozen research
papers not only shed light on the understanding of the different
selectivity of modern steroid receptors for their corresponding
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hormones, but also answered some long standing questions
in the field, including the role of epistasis in macromolecular
evolution. Recently, ASR has leaped over to successfully recreate
ancestral enzymes with reaction efficiencies near that of modern
day enzymes (Perez-Jimenez et al., 2011; Hobbs et al., 2012;
Ingles-Prieto et al., 2013; Risso et al., 2013; Boucher et al., 2014).
Resurrection of enzymes has been an important step in validating
the accuracy of ASR because of the need to maintain enzymatic
activity, which is extremely sensitive to mutational change. These
studies have largely focused on understanding changes in the
enzyme’s melting temperatures or underlying structural changes.
The Gleevec story takes it to the next step to characterize
the evolution of energy landscapes that ultimately underlies
function.
“Tell Us What the Future Holds, So We May
Know That You Are Gods” (Isaiah 41, 23)
How can understanding of Gleevec selectivity and the differential
evolution of kinases guide the creation of better cancer drugs?
We are not god, we do not have the ultimate answer. However
the door to intelligent design of successful cancer therapeutics
may have opened a little wider with recent advances in
genome information including ASR and personal genomic
profiling, characterization of free energy landscapes of the drug
binding process to targets, advances in medicinal chemistry and
computation.
The history of Gleevec research teaches us a number of
lessons: First, the correct microscopic binding model (meaning
the correct scheme), ideally with quantification of each step,
is crucial. Slow progress in understanding Gleevec’s selectivity
was in large extent due to the overwhelming attention to the
DFG-loop conformational selection model (Cowan-Jacob et al.,
2005; Dar et al., 2008; Shan et al., 2009; Aleksandrov and
Simonson, 2010; Lovera et al., 2012; Lin and Roux, 2013; Lin
et al., 2014). Second, the physical binding step that has been
the major focus in docking simulations is only one piece of
the puzzle, and conformational changes are crucially linked to
both affinity and selectivity (Figure 2C). Therefore, experimental
and computational efforts should be more centered on the
dynamics of the target and drug/target complex. Third, the
trivial (simple laws of thermodynamics) but at the same time
profound recognition that conformational change after binding
(an induced fit step) delivers two essential components of a good
drug: increased affinity and long drug residence times on the
target (Figure 2C). In addition, it can provide excellent specificity
particularly when such conformational changes involve elements
remote from the binding site as seen in Abl-Gleevec. In contrast,
conformational selection (ability of the apo protein to sample
multiple conformations) by definition weakens the overall drug
affinity by the fraction of the protein in the binding-incompetent
states. While such a step can offer drug specificity, the new results
suggest that DFG-loop conformational selection seems to play
only a minor role for kinase selectivity due to the fact that the
DFG-loop readily interconverts between states. We propose that
induced fit steps are in play in many successful drugs leading to
very tight binding and long on-target residence times. Finally,
molecular dynamics simulations will play an increasing role in
rational drug design, but such simulations need to be based
on the solid foundation of biochemical research. In the case
of Gleevec and other kinase inhibitors, future computational
emphasize should be centered on dynamics of the enzyme/drug
complex characterizing the induced fit step and not on the DFG-
loop dynamics. Having the correct binding scheme established
with corresponding structural information available, MD can
sample the conformational space identifying new local minima
and potentially cryptic or allosteric sites that are hard to trap
experimentally if they are low-populated. If such states are unique
for a particular kinase, they can be excellent targets for new
specific inhibitors.
We are excited about the future prospect of a happy marriage
between experiments and computation, and between basic
academic research and pharmaceutical industry to tackle the very
challenging but rewarding goal of designing perfect weapons
against deadly diseases.
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